Methotrexate, etoposide, ifosfamide and cisplatin (MVIP): An effective first-line therapy for IGCCC intermediate/poor prognosis patients with germ-cell tumors. Single institution experience

Journal of B.U.ON.

Volumn 7, Issue 1, 2002, Pages 35-41

  Athanassiou, A E ^a   Potamianou, A ^a   Bountouroglou, N ^a   Ziras, N ^a   Frangoulidis, A ^a   Varthalitis, J ^a   Karvounis, N ^a   Chrysanthou, C ^a   Pectasidis, D ^a  

^a METAXA CANCER HOSPITAL   (Greece)

Author keywords

Chemotherapy; Germ cell tumors; IGCCC; Intermediate poor prognosis; MVIP; Testicular cancer

Indexed keywords

ALPHA FETOPROTEIN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BICARBONATE; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; LACTATE DEHYDROGENASE; MESNA; METHOTREXATE;

ADOLESCENT; ADULT; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DIURESIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FOLLOW UP; GERM CELL TUMOR; HUMAN; HYDRATION; LONG TERM CARE; MALE; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PHASE 2 CLINICAL TRIAL; PRIMARY HEALTH CARE; PROGNOSIS; PROSPECTIVE STUDY; PROTECTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 0036248419     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Classification and frequency of testicular tumours
2. Neoplastic transformation of testicular germ cells
3. The cytogenic theory of the pathogenesis of human adult male germ cell tumours
4. Allelic losses in carcinoma in situ and testicular germ cell tumours of adolescents and adults: Evidence suggestive of linear progression model
5. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer
6. Prognostic factors for favorable outcome in disseminated germ cell tumors
7. Current optimum management of anaplastic germ cell tumours of the testis and other sites
8. Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: Comparison of commonly used classification systems of good and poor prognosis
9. Poor-risk germ cell tumours. Recent developments
10. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer
11. Prognostic factors in advanced nonseminomatous germ cell testicular tumours: Results of a multicentre study
12. International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers
13. The second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors
14. Non parametric estimation from incomplete observations
15. Treatment of disseminated germ cell tumors with cisplatin, bleomycin and either vinblastine or etoposide
16. Accelerated induction chemotherapy (C-BOP-BEP) for poor and intermediate prognosis metastatic germ cell tumours
17. POMB/ACE chemotherapy for advanced non-seminomatous germ cell tumours in men
18. High dose chemotherapy with hematopoietic stem cell support in poor prognosis non seminomatous germ cell tumours (NSGCT)
19. High-dose (HD) VIP chemotherapy plus peripheral stem cell support as first-line therapy for advanced germ cell cancer
20. High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: An effective first-line therapy with minimal toxicity
21. High dose chemotherapy (HDC) incorporated into initial poor risk non-seminomatous germ cell tumours (NSGCT)
22. BOMP-EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ cell tumours: The Spanish Germ-Cell Cancer Group experience
23. Early intensified chemotherapy with autologous bone marrow transplantation in first-line treatment of poor risk non-seminomatous germ-cell tumours. Preliminary results of a French randomized trial
24. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ-cell tumours
25. Re-analysis of the Intergroup Trial (E 3887) of cisplatin and etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumours using the International Germ Cell Consensus Classification
26. Improved long-term survival of patients with metastatic nonseminomatous germ cell cancer during the cisplatin era in relation to prognostic classifications